Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full – year guidance

Basel, October 27, 2015 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis continued to make strong progress on innovation and key launches in the third quarter. The Pharmaceuticals and Sandoz Divisions continue to perform exceptionally well, offsetting softness in the Alcon Division. Entresto was approved and launched in the US, and Tafinlar + Mekinist was approved in the EU for BRAF-mutant melanoma. We confirm our full – year guidance.”

  • Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing …
/by